Vol. 13, No. 2
The Winthrop Legacy: People That Made a Difference in Our Community
Winthrop-University Hospital Cardiac Team One of First on L.I. to Use Drug-Coated Stent During Surgery
Winthrop-University Hospital Announces Anti-Slime Compound Could Be Used
on Space Station
Winthrop-University Hospital Physicians Perform Groundbreaking New Procedure to Decrease Recurrance of Coronary Artery Blockages
Winthrop Puts Golfers in The Swing of Things
Garden City High School Seniors 'Pay it Forward' for Patients at Winthrop-University Hospital
Winthrop's Pediatric Task Force Leads Fundraising Initiative for New Pediatric Inpatient Center
Winthrop-University Hospital Helps Seniors Sort Out Mysteries of Medication
Winthrop-University Hospital Orthopaedic Surgeon Performs New, Small Incision Minimally Invasive Hip Replacement Procedure
Winthrop-University Hospital's 2nd Hispanic Health Fair Successfully Reaches Out to Hundreds in Community
Winthrop-South Nassau University Health System Joins New York's Largest Healthcare System
Golden Goose Gala Visits The Roaring 20s - Save the Date - November 15, 2003!
Back to Publications
inthrop-University Hospital has launched a collaboration with The Boeing Company to further develop and test a new class of compounds, developed by Winthrop. The class of compounds is currently being tested for their ability to inhibit bacterial growth and biofilm formation on systems in the International Space Station (ISS).
BT inventor Philip Domenico, PhD Senior Scientist, Winthrop's Cardiopulmonary Research Institute (seated), is joined by his colleagues (l-r) Jonathan Davis, MD, Director of Neonatology at Winthrop, and Jeffrey Kazzaz, PhD, Research Director, Winthrop's Cardiopulmonary Research Institute.|
The compounds, called bismuth thiols (BT), were invented by Philip Domenico, PhD, from Winthrop's Cardiopulmonary Research Institute. Dr. Domenico discovered that BTs inhibit the formation of bacterial biofilms or bacterial "slime" that can build up on the surfaces of critical equipment, which can ultimately result in poorer performance-a significant problem on earth and in space.
Working with Dr. Domenico, scientists at The Boeing Company have performed preliminary tests on several of Winthrop's compounds, and they have synthesized and tested a number of new bismuth thiol compounds. One of the newly synthesized compounds has been selected as a promising candidate for possible use in the ISS.
Boeing has a contract with the National Aeronautics and Space Administration (NASA) to solve potential problems related to possible biofilm build-up on heat exchange systems, which could reduce the operating efficiency of the equipment. Boeing will perform the tests and simulations needed to ensure the stability, compatibility, safety, and efficacy of the BT compound before it can be used on the ISS.
Left to Right: Daniel Walsh, President and CEO of Winthrop-University Hospital, Richard A. Newhouse, Jr., outgoing Chairman of the Board, and Patrick K. Long, Winthrop's new Chairman of the Board.
At Winthrop-University Hospital's annual Board of Directors meeting on June 12, tribute was paid to Mr. Richard A. Newhouse, Jr., outgoing Chairman of the Board. Mr. Newhouse was presented with a plaque and gift for his loyalty, devotion, and inspiration to Winthrop's mission. His outstanding leadership has proven vital to the growth and development of the hospital over the past three years. |
"BTs are unusual in their ability to inhibit biofilms at minute (low parts per million) concentrations, which makes them potentially useful in a wide variety of applications," said Dr. Domenico. "For example, they [biofilms] play a central role in lung infections and contribute to antibiotic resistance. My collaborators from around the world are exploring the use of BTs to solve both clinical and industrial problems."
"Winthrop's groundbreaking research has widespread potential application," commented John Aloia, MD, Chief Academic Officer. "We are proud of our research team, and look forward to future collaborations that could lead to licensing the technology for commercial applications."
For further information about research at Winthrop-University Hospital, call Mr. Alexander Schoen at (516) 663-8997.